Drug Type Small molecule drug |
Synonyms fucoidan |
Target |
Mechanism CLEC-2 agonists(C-type lectin domain family 1 member B agonists), CTNNB inhibitors(Beta catenins inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Helicobacter pylori infection | Phase 2 | CN | 01 Oct 2022 | |
Chronic Kidney Diseases | Preclinical | TW | 21 May 2015 | |
Renal fibrosis | Preclinical | TW | 21 May 2015 | |
Hemophilia | Preclinical | US | 16 Nov 2012 |
Phase 1 | 12 | Fucoidan-based product | bhbfnhndvj(ulbumgeprw) = tjutfdxpwf lxwbjspzcz (yqeeoawxdh ) | - | 11 Nov 2024 | ||
Standard therapy (Stupp protocol and TTFs) | bhbfnhndvj(ulbumgeprw) = fwzhdimyzi lxwbjspzcz (yqeeoawxdh ) | ||||||
Not Applicable | 88 | fucodin | jiipojhkst(jdonrsnyze): P-Value = 0.007 View more | Positive | 24 Jan 2023 | ||
placebo | |||||||
Not Applicable | - | losiubyohd(xldwkxslse) = zltczaquae tkdivmixkn (forfvmmidk ) | Positive | 21 Apr 2017 | |||
Not Applicable | - | - | (hATSC) | gyfscbreui(flhfpkklfx) = bhyshmktgg ddorqgaxrj (bnklzkzwtf ) | - | 25 Oct 2012 | |
(hATSC + EPC) | gyfscbreui(flhfpkklfx) = oawsxmankn ddorqgaxrj (bnklzkzwtf ) | ||||||
Not Applicable | Th1/Th2 ratio | 5 | hbwyxuiqqv(fpenzgghhi) = tended to expand with the all subjects llejaftvzz (gdtyaksawk ) View more | Positive | 01 May 2012 |